Is Albireo Pharma, Inc. (ALBO) a Buy, Sell, or Hold?
Albireo Pharma, Inc.
NASDAQ:ALBO
$44.15 USD
$0 (0.0%)
- Volume
- 1.24M
- Average Volume
- 591.26K
- Market Capitalization
- $915.89M
- P/E Ratio
- -5.61
- Dividend Yield
- 0.00%
- Price Target
- $42.00
- Year High
- $45.23
- Year Low
- $16.02
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.93
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Ronald H. W. Cooper |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ALBO |
| CUSIP | 01345P106 |
| CIK | 0001322505 |
| Web | https://www.albireopharma.com |
| Phone | 857 254 5555 |
| Currency | USD |
| Employees | 130 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.06 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.93 |
| Quick Ratio | 5.93 |
| Cash Ratio | 5.47 |
Sales & Book Value
| Annual Sales | $40.58M |
| Price / Sales | 22.57 |
| Cash Flow | -5.62 |
| Price / Cash Flow | -8.48 |
| Price / Book | 4.83 |
Price Target and Rating
| Average Stock Price Forecast | $42.00 |
| High Stock Price Forecast | $48.00 |
| Low Stock Price Forecast | $42.00 |
| Forecast Upside/Downside | 5.12% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 12 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-7.87 |
| Trailing P/E Ratio | -5.61 |
| PEG Ratio | 0.02 |
| P/E Growth | 0.02 |
| Net Income | $-151.35M |
| Net Margin | -372.97% |
| Pretax Margin | -83.86% |
| Return on Equity | -84.83% |
| Return on Assets | -50.11% |
Financials Score
| AltmanZ Score | 0.51 |
| Piotroski Score | 4.00 |
| Working Capital | 201.02M |
| Total Assets | 321.22M |
| Ebit | -103.7M |
| Market Cap | 915.89M |
| Total Liabilities | 221.15M |
Poll Results
About Albireo Pharma, Inc. (NASDAQ:ALBO) Stock
Albireo Pharma, Inc. is a biopharmaceutical company with marketed products, dedicated to researching, developing, and commercializing new treatments that modify bile acids. The company primarily targets rare liver diseases in children, as well as various other conditions affecting the liver or digestive system. Its portfolio includes Bylvay, a treatment approved for progressive familial intrahepatic cholestasis. Bylvay is also in advanced (Phase III) clinical trials for further pediatric indications such as biliary atresia and Alagille syndrome, which are both uncommon and serious childhood disorders. Additionally, Albireo offers Elobixibat, prescribed for the management of persistent constipation and other functional gastrointestinal issues. Albireo is further advancing its pipeline with ... A3907, currently undergoing early-stage (Phase I) clinical investigation for adult liver diseases, and A2342, a preclinical candidate designed to address adult viral and liver conditions. The company holds a licensing agreement with EA Pharma Co., Ltd. concerning the development and market rollout of Elobixibat. Albireo Pharma, Inc.'s headquarters are located in Boston, Massachusetts.
Albireo Energy Announces CEO Succession as Company Enters Next Stage of Accelerated Expansion
2026-06-22 07:00:00
EDISON, N.J.--(BUSINESS WIRE)--Albireo Energy, a leading independent building controls and energy services provider and a Huron Capital portfolio company, today announced that Kevin Baxter has been appointed CEO, a leadership transition that reinforces the company's momentum and affirms Huron Capital's confidence in Albireo Energy's long-term strategy. Larry G. Wash, who has served as both co-Chairman and CEO, will continue as co-Chairman. Since 2023, Baxter has been serving as President, playi.
Frequently Asked Questions
-
What is the current Albireo Pharma, Inc. (ALBO) stock price?
-
Albireo Pharma, Inc.(NASDAQ:ALBO) stock price is $44.15 in the last trading session. During the trading session, ALBO stock reached the peak price of $45.23 while $16.02 was the lowest point it dropped to. The percentage change in ALBO stock occurred in the recent session was 0.0% while the dollar amount for the price change in ALBO stock was $0.
-
ALBO's industry and sector of operation?
-
The NASDAQ listed ALBO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ALBO?
-
Ronald H. W. Cooper | Chief Executive Officer, Pres & Director
Martha J. Carter | Chief Regulatory Officer
Jason G. Duncan | Chief Legal Officer, Gen. Counsel & Sec.
Simon Nicolas Reade Harford | Chief Financial Officer & Treasurer
Joan Connolly | Chief Technology Officer -
How many employees does ALBO have?
-
Number of ALBO employees currently stands at 130. ALBO operates from 10 Post Office Square, Boston, MA 02109, US.
-
Link for ALBO official website?
-
Official Website of ALBO is: https://www.albireopharma.com
-
How do I contact ALBO?
-
ALBO could be contacted at phone #857 254 5555 and can also be accessed through its website. ALBO operates from 10 Post Office Square, Boston, MA 02109, US.
-
How many shares of ALBO are traded daily?
-
The average number of ALBO shares traded daily for last 3 months was 591.26K.
-
What is the market cap of ALBO currently?
-
The market value of ALBO currently stands at $915.89M with its latest stock price at $44.15